rxstat › Shortages › Mesalazine

Mesalazine (Salofalk, Mezera) shortage status

No current shortage

Source: Health Canada shortage reports · Updated Aug 8, 2026

Also sold as: Salofalk, Mezera, Asacol, Octasa

Mesalazine has no current shortage reported in Canada. It has been in shortage before; the history is below.

An anti-inflammatory medicine used to treat inflammatory bowel disease such as ulcerative colitis.

Products affected
0 / 12
Reports on file
36

Shortage history

2023 2024 2025 2026

Shortage history (red bands = periods in shortage).

Reports by product

The DIN is printed on your prescription label.

To be discontinued
SALOFALK
500MG · SUPPOSITORY · ABBVIE CORPORATION
DIN 02112760
To be discontinued
SALOFALK
1000MG · SUPPOSITORY · ABBVIE CORPORATION
DIN 02242146
Resolved
MEZAVANT
1.2G · TABLET (DELAYED AND EXTENDED RELEASE) · TAKEDA CANADA INC
DIN 02297558 · ended Jul 29, 2026 · Delay in shipping of the drug.
To be discontinued
SALOFALK
4G · SUSPENSION · ABBVIE CORPORATION
DIN 02112809
To be discontinued
SALOFALK
2G · SUSPENSION · ABBVIE CORPORATION
DIN 02112795
Resolved
MEZAVANT
1.2G · TABLET (DELAYED AND EXTENDED RELEASE) · TAKEDA CANADA INC
DIN 02297558 · ended Apr 28, 2026 · Delay in shipping of the drug.
Resolved
OCTASA
800MG · TABLET (DELAYED-RELEASE) · TILLOTTS PHARMA AG
DIN 02465752 · ended Mar 6, 2026 · Delay in production
Resolved
TEVA-5 ASA
400MG · TABLET (ENTERIC-COATED) · TEVA CANADA LIMITED
DIN 02171929 · ended Jan 7, 2026 · Disruption of the manufacture of the drug.
Resolved
TEVA-5 ASA
400MG · TABLET (ENTERIC-COATED) · TEVA CANADA LIMITED
DIN 02171929 · ended Jan 7, 2026 · Disruption of the manufacture of the drug.
Resolved
TEVA-5 ASA
400MG · TABLET (ENTERIC-COATED) · TEVA CANADA LIMITED
DIN 02171929 · ended Oct 1, 2025 · Disruption of the manufacture of the drug.
Resolved
TEVA-5 ASA
400MG · TABLET (ENTERIC-COATED) · TEVA CANADA LIMITED
DIN 02171929 · ended Apr 16, 2025 · Disruption of the manufacture of the drug.
Resolved
TEVA-5 ASA
400MG · TABLET (ENTERIC-COATED) · TEVA CANADA LIMITED
DIN 02171929 · ended Apr 9, 2025 · Disruption of the manufacture of the drug.

Showing 12 of 36 reports. All reports are on file with Health Canada.

What's happening

There are no active shortage reports for Mesalazine. Health Canada has 36 historical reports on file for this drug, so supply has been disrupted before; the change log below shows the history.

Mesalazine is classified under “INTESTINALANTIINFLAMMATORY AGENTS” (ATC A07EC).

Recent changes

Common questions

What is Mesalazine used for?

An anti-inflammatory medicine used to treat inflammatory bowel disease such as ulcerative colitis.

When will Mesalazine be back in stock in Canada?

Mesalazine has no active shortage; supply is normal per Health Canada reports.

Why is Mesalazine in shortage?

It isn't currently. Past reports and their reasons are listed above.

What can my pharmacist do about it?

Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.

Email alerts

Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.

Related drugs (intestinalantiinflammatory agents)

Cromolyn (Opticrom) Partial shortage 2 of 5 reported products affected Olsalazine (Dipentum) Partial shortage 1 of 1 reported products affected

Guides: what to do when your medication is in shortage · how to read shortage reports

Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.